Live Breaking News & Updates on Er2 Negative Disease

Lida A. Mina, MD, discusses the evolving role of ADCs across breast cancer subtypes, current data on the use of CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer, and the increased use of genomic testing and NGS to improve the sequencing of agents in triple-negative breast cancer. ....

United States , Lidaa Mina , Karens Anderson , Felipe Batalini , Banner Md Anderson Cancer Center , Division Of Hematology , Women Cancer Program , Mayo Clinic Comprehensive Cancer Center , Cancer Program , Mayo Arizona Breast Cancer , Medical Oncology , Science Summit , Shakeela Bahadur , Cancer Center , Mayo Clinic Comprehensive Cancer , Her2 Positive And Low Breast Cancer , Fam Trastuzumab Deruxtecan Nxki , Personalized Medicine , Next Generation Sequencing , Antibody Drug Conjugates , Cdk4 6 Inhibitors , Hr Positive , Er2 Negative Disease ,